Sex disparities in non-small cell lung cancer: mechanistic insights from a cRaf transgenic disease model

EBioMedicine. 2023 Sep:95:104763. doi: 10.1016/j.ebiom.2023.104763. Epub 2023 Aug 23.

Abstract

Background: Women are at greater risk of developing non-small cell lung cancer (NSCLC), yet the underlying causes remain unclear.

Methods: We performed whole genome scans in lung tumours of cRaf transgenic mice and identified miRNA, transcription factor and hormone receptor dependent gene regulations. We confirmed hormone receptors by immunohistochemistry and constructed regulatory gene networks by considering experimentally validated miRNA-gene and transcription factor-miRNA/gene targets. Bioinformatics, genomic foot-printing and gene enrichment analysis established sex-specific circuits of lung tumour growth. Translational research involved a large cohort of NSCLC patients. We evaluated commonalities in sex-specific NSCLC gene regulations between mice and humans and determined their prognostic value in Kaplan-Meier survival statistics and COX proportional hazard regression analysis.

Findings: Overexpression of the cRaf kinase elicited an extraordinary 8-fold increase in tumour growth among females, and nearly 70% of the 112 differentially expressed genes (DEGs) were female specific. We identified oncogenes, oncomirs, tumour suppressors, cell cycle regulators and MAPK/EGFR signalling molecules, which prompted sex-based differences in NSCLC, and we deciphered a regulatory gene-network, which protected males from accelerated tumour growth. Strikingly, 41% of DEGs are targets of hormone receptors, and the majority (85%) are oestrogen receptor (ER) dependent. We confirmed the role of ER in a large cohort of NSCLC patients and validated 40% of DEGs induced by cRaf in clinical tumour samples.

Interpretation: We report the molecular wiring that prompted sex disparities in tumour growth. This allowed us to propose the development of molecular targeted therapies by jointly blocking ER, CDK1 and arginase 2 in NSCLC.

Funding: We gratefully acknowledge the financial support of the Lower Saxony Ministry of Culture and Sciences and Volkswagen Foundation, Germany to JB (25A.5-7251-99-3/00) and of the Chinese Scholarship Council to SZ (202008080022). This publication is funded by the Deutsche Forschungsgemeinschaft (DFG) as part of the "Open Access Publikationskosten" program.

Keywords: Clinical validation; Hormone receptors; Lung cancer; Regulatory gene network; cRaf.

MeSH terms

  • Animals
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Female
  • Humans
  • Lung Neoplasms* / genetics
  • Male
  • Mice
  • Mice, Transgenic
  • MicroRNAs*
  • Proto-Oncogene Proteins c-raf / genetics
  • Proto-Oncogene Proteins c-raf / metabolism
  • Receptors, Estrogen / metabolism

Substances

  • MicroRNAs
  • Proto-Oncogene Proteins c-raf
  • Receptors, Estrogen